DXCM vs SENS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DXCM and SENS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DXCM and SENS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

DexCom is a medical-device company that pioneered continuous glucose monitoring. Its wearable sensors and transmitters measure glucose levels continuously and send readings to a phone or receiver, replacing or supplementing traditional fingerstick tests for people with diabetes. Its flagship G7 platform serves people with type 1 and type 2 diabetes, while Stelo, an over-the-counter CGM cleared for people who do not use insulin, extends the technology toward a broader wellness and metabolic-health audience. DexCom earns most of its revenue from recurring sensor sales, since users replace sensors regularly, which gives the business a razor-and-blade-like recurring quality once a patient is on the platform.

Full DXCM guide

Senseonics Holdings develops and commercializes Eversense, a continuous glucose monitoring system for people with diabetes built around a small sensor implanted just under the skin of the upper arm. Unlike the disposable adhesive sensors from Dexcom and Abbott that last roughly 10 to 15 days, Eversense is designed for long-term wear, and the current Eversense 365 version is approved for up to one year on a single sensor, paired with a removable transmitter and a phone app. The long-wear, low-maintenance profile is the company's core differentiator in an otherwise patch-dominated category.

Full SENS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DXCM drivers: Expansion beyond insulin users; New products and features.
• SENS drivers: Eversense 365 one-year differentiation; Bringing commercialization in-house from Ascensia.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The main risk is that DexCom carries a premium valuation built on continued high growth, so any slowdown, guidance cut, or margin disappointment can pressure the stock sharply. For SENS, senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DXCM if you believe its drivers more; SENS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DXCM and SENS guides.

DXCM. Figures are approximate and tied to the asOf date; verify live numbers before acting. DexCom typically trades at a premium valuation that reflects expectations for sustained double-digit growth, so its earnings multiple tends to be higher than the broader market; that premium leaves less room for error if growth slows or competition intensifies. Investors should weigh the CGM growth runway and coverage momentum against that elevated valuation and Abbott's competitive presence.

SENS. These figures describe a speculative growth company, not a mature one: revenue is rising quickly off a small base while net losses remain large relative to sales. Cash on hand and recent financing support the Eversense 365 launch and pipeline, but continued losses mean future capital raises are possible. All figures are approximate and tied to the asOf date; verify against the latest filings before acting.

Headline figures (approximate, Jul 2026): DXCM shows revenue (q1 2026) ~$1.19 billion, up about 15% year over year, net income (q1 2026) ~$199.5 million, or about $0.51 per share, 2026 revenue guidance $5.16 to $5.25 billion (reiterated), coverage expansion targeting more than 7 million covered type 2 non-insulin lives by year end; SENS shows full-year 2025 revenue ~$35.3M (up from ~$22.5M in 2024), q1 2026 revenue ~$11.7M (up ~87% year over year), full-year 2026 revenue guidance ~$60M to $64M (raised; ~70-82% growth), q1 2026 net loss ~$32.3M (vs ~$14.3M a year earlier).

DXCM and SENS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DXCM and SENS exposure against your real portfolio. It is not an investment adviser.